Bart Neyns

Bart Neyns

UNVERIFIED PROFILE

Are you Bart Neyns?   Register this Author

Register author
Bart Neyns

Bart Neyns

Publications by authors named "Bart Neyns"

Are you Bart Neyns?   Register this Author

100Publications

4334Reads

8Profile Views

Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma.

Int J Radiat Oncol Biol Phys 2019 Apr 3. Epub 2019 Apr 3.

Department of Radiation Oncology, Ghent University Hospital, Belgium; Cancer Research Institute Ghent (CRIG), Belgium.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03603016193056
Publisher Site
http://dx.doi.org/10.1016/j.ijrobp.2019.03.041DOI Listing
April 2019

Anaphylaxis-like reaction to anti-BRAF inhibitor dabrafenib confirmed by drug provocation test.

Melanoma Res 2019 02;29(1):95-98

Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00008390-900000000-9923
Publisher Site
http://dx.doi.org/10.1097/CMR.0000000000000529DOI Listing
February 2019

Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab.

Cancer Med 2018 Oct 21;7(10):4870-4879. Epub 2018 Aug 21.

Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1726DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198218PMC
October 2018

Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods.

Arch Pathol Lab Med 2018 08 2;142(8):982-991. Epub 2018 Apr 2.

From the Departments of Immunohistochemistry (Drs Schats, Van Vré, Boeckx, and Schrijvers and Ms De Bie) and Molecular Pathology (Dr Kockx), HistoGeneX, Antwerp, Belgium; the Department of Medical Biochemistry, University of Antwerp, Antwerp, Belgium (Drs Schats and De Meester); and the Department of Medical Oncology, Universitair Ziekenhuis Brussel, Belgium (Dr Neyns).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2017-0159-OADOI Listing
August 2018

Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition.

Blood Adv 2018 08;2(16):2156-2158

Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018021782DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113614PMC
August 2018

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

J Clin Oncol 2018 Mar 20;36(8):773-779. Epub 2018 Jan 20.

Michael J. Overman and Scott Kopetz, University of Texas MD Anderson Cancer Center, Houston, TX; Sara Lonardi, Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padova; Fabio Gelsomino, University Hospital of Modena, Modena; Massimo Aglietta, Institute for Cancer Research and Treatment of Candiolo, University of Torino Medical School, Turin, Italy; Ka Yeung Mark Wong, Sydney Medical School, University of Sydney, Sydney, New South Wales; Andrew Hill, Tasman Oncology Research, Ltd., Southport, Queensland, Australia; Heinz-Josef Lenz, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Michael A. Morse, Duke University Medical Center, Durham, NC; Eric Van Cutsem, University Hospitals Gasthuisberg Leuven and Katholieke Universiteit Leuven, Leuven; Alain Hendlisz, Institut Jules Bordet; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels; Jean-Marie Ledeine, Bristol-Myers Squibb, Braine-L'Alleud, Belgium; Ray McDermott, St Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland; Michael B. Sawyer, Cross Cancer Institute and University of Alberta, Edmonton, Alberta, Canada; Magali Svrcek and Thierry André, Hopital Saint Antoine, Assistance Publique Hôpitaux de Paris and Sorbonne Universités, Université Pierre et Marie Curie, Paris, France; and Rebecca A. Moss, Z. Alexander Cao, and Shital Kamble, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.76.9901
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.76.9901DOI Listing
March 2018

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

J Clin Oncol 2018 Feb 3;36(4):383-390. Epub 2017 Jul 3.

James Larkin, Royal Marsden NHS Foundation Trust, London; Paul Lorigan, The Christie National Health Service Foundation Trust, Manchester, United Kingdom; David Minor, California Pacific Medical Center Research Institute; Adil Daud, University of California San Francisco, San Francisco; Bartosz Chmielowski, University of California, Santa Monica, CA; Sandra D'Angelo, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; Jeffrey Weber, Perlmutter Cancer Center at New York University-Langone Medical Center, New York; Nikhil Khushalani, Roswell Park Cancer Institute, Buffalo, NY; Gerald Linette, Washington University, St. Louis, MO; Christopher D. Lao, University of Michigan, Ann Arbor, MI; Kenneth Grossmann, Huntsman Cancer Institute, Salt Lake City, UT; Mario Sznol, Yale Comprehensive Cancer Center, New Haven, CT; Jeffrey Sosman, Northwestern University, Chicago, IL; Dana Walker, George Kong, and Christine Horak, Bristol-Myers Squibb, Princeton, NJ; Bart Neyns, University Hospital, Vrije Universiteit Brussel, Brussels, Belgium; Michael Smylie, Cross Cancer Institute, Edmonton, Alberta; Wilson H. Miller Jr, Jewish General Hospital and Segal Cancer Centre, McGill University, Montreal, Quebc, Canada; Ralf Gutzmer, Medizinische Hochschule Hannover, Hannover; Jessica C. Hassel, Nationale Centrum für Tumorerkrankungen Heidelberg, Heidelberg; Dirk Schadendorf, University Hospital Essen, Essen, Germany; and Christoph Hoeller, Medical University of Vienna, Wien, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.8023DOI Listing
February 2018

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

Eur J Cancer 2017 07 11;79:176-184. Epub 2017 May 11.

Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia; Discipline of Medicine, University of Adelaide, Adelaide, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.04.007DOI Listing
July 2017

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

J Clin Oncol 2017 Jan 7;35(2):226-235. Epub 2016 Nov 7.

Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.67.9258
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.67.9258DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559888PMC
January 2017

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.

J Clin Endocrinol Metab 2016 11 29;101(11):4431-4439. Epub 2016 Aug 29.

Departments of Endocrinology (J.d.F., B.V., B.B.), Medical Oncology (Y.J., M.S., B.N.), and Nuclear Medicine (H.E.), Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2016-2300DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095250PMC
November 2016

Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs.

Am J Cancer Res 2016 1;6(11):2514-2531. Epub 2016 Nov 1.

Laboratory of Molecular and Cellular Therapy, Vrije Universiteit Brussel Laarbeeklaan 103E, 1090, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126270PMC
November 2016

Bone Marrow Metastases from a 1p/19q Co-deleted Oligodendroglioma - A Case Report.

Anticancer Res 2016 Aug;36(8):4145-9

Department of Medical Oncology, UZ Brussel, Brussels, Belgium

View Article

Download full-text PDF

Source
August 2016

Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.

Cancer Immunol Immunother 2016 06 20;65(6):727-40. Epub 2016 Apr 20.

Laboratory of Molecular and Cellular Therapy, Vrije Universiteit Brussel, Laarbeeklaan 103E, 1090, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-016-1836-3DOI Listing
June 2016

Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma.

Melanoma Res 2016 Apr;26(2):157-63

aDepartment of Medical Oncology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels bBiocartis, Mechelen cDepartment of Dermatology, Universitair Ziekenhuis Gent (UZ Gent), Universiteit Gent (UGent), Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000224DOI Listing
April 2016

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.

J Clin Oncol 2016 Apr 29;34(12):1330-8. Epub 2016 Feb 29.

Sofie Wilgenhof, Kris Thielemans, and Bart Neyns, Universitair Ziekenhuis Brussel; Sofie Wilgenhof, Jurgen Corthals, Carlo Heirman, Kris Thielemans, and Bart Neyns, Vrije Universiteit Brussel; Nicolas van Baren, Ludwig Institute for Cancer Research; Sophie Lucas, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium; and Pia Kvistborg, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.4121DOI Listing
April 2016

Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.

Melanoma Res 2015 Dec;25(6):550-4

Departments of aMedical Oncology bNephrology cPathology, Universitair Ziekenhuis Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000186DOI Listing
December 2015

Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma.

Anticancer Res 2015 Dec;35(12):6893-9

Department of Medical Oncology, Oncology Centre, University Hospital Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
December 2015

Complete Cytologic Remission of V600E BRAF-Mutant Melanoma-Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib.

J Clin Oncol 2015 Oct 14;33(28):e109-11. Epub 2014 Apr 14.

Universitair Ziekenhuis Brussel, Brussels, Belgium

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.48.7298
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.48.7298DOI Listing
October 2015

Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.

Anticancer Res 2015 Oct;35(10):5551-7

Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium

View Article

Download full-text PDF

Source
October 2015

Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?

Melanoma Res 2015 Aug;25(4):357-61

Departments of aDermatology bMedical Oncology, Ghent University Hospital, Ghent cDepartment of Medical Oncology, UZ-Brussel, Brussels, Belgium dToxicology Laboratory, CHU Lille, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000171DOI Listing
August 2015

Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients.

Oncoimmunology 2015 Aug 1;4(8):e1019197. Epub 2015 Apr 1.

Department of Tumor Immunology (Radboud Institute for Molecular Life Sciences); Radboud university medical centre ; Nijmegen, The Netherlands ; Medical Oncology; Radboud university medical centre ; Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2015.1019197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570143PMC
August 2015

Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.

Melanoma Res 2015 Apr;25(2):180-3

aDepartment of Medical Oncology, University Hospital Brussels Departments of bDermatology cPathology dNuclear Medicine, Erasme Hospital, Brussels, Belgium.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00008390-201504000-000
Publisher Site
http://dx.doi.org/10.1097/CMR.0000000000000145DOI Listing
April 2015

Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model.

Oncoimmunology 2015 Apr 22;4(4):e998107. Epub 2015 Jan 22.

Laboratory of Molecular and Cellular Therapy; Department of Immunology-Physiology; Vrije Universiteit Brussel , Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2014.998107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485747PMC
April 2015

Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases.

Cancer Immunol Immunother 2015 Mar 30;64(3):381-8. Epub 2014 Dec 30.

Medical Oncology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-014-1642-8DOI Listing
March 2015

Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure.

Melanoma Res 2015 Feb;25(1):68-74

aDepartment of Medical Oncology, UZ Brussels bDepartment of Dermatology, Hospital Erasme, Brussels cDepartment of Dermatology, UZ Gent, Ghent, Belgium.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/CMR.0000000000000131DOI Listing
February 2015

Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula.

Cancer Immunol Immunother 2014 Sep 31;63(9):959-67. Epub 2014 May 31.

Laboratory of Molecular and Cellular Therapy & Dendritic Cell-bank, Vrije Universiteit Brussel, Laarbeeklaan 103E, 1090, Brussels, Belgium,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-014-1558-3DOI Listing
September 2014

AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells.

Oncotarget 2014 Aug;5(16):6801-15

Laboratory of Molecular and Cellular Therapy, Department of Immunology-Physiology, Vrije Universiteit Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196164PMC
http://dx.doi.org/10.18632/oncotarget.2254DOI Listing
August 2014

Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL).

Biomed Res Int 2013 3;2013:976383. Epub 2013 Jan 3.

Laboratory of Molecular and Cellular Therapy, Department of Immunology-Physiology and Dendritic Cell Bank, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/976383DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581259PMC
November 2013

Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy.

Clin Cancer Res 2013 Oct;19(19):5292-9

Authors' Affiliations: Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland; and Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0261DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845447PMC
October 2013

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.

J Clin Oncol 2013 Sep 12;31(26):3212-8. Epub 2013 Aug 12.

Tracy T. Batchelor, Rakesh K. Jain, and Gregory Sorensen, Massachusetts General Hospital, Boston, MA; Paul Mulholland, University College London, London; Rao Gattamaneni, the Christie Foundation Trust Hospital, Manchester, United Kingdom; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; L. Burt Nabors, University of Alabama at Birmingham, Birmingham, AL; Mario Campone, Centre Rene Gauducheau, Saint-Herblain, France; Antje Wick, University of Heidelberg, Heidelberg, Germany; Warren Mason, Princess Margaret Hospital, Toronto, Ontario, Canada; Tom Mikkelsen, Henry Ford Hospital, Detroit, MI; Surasak Phuphanich, Cedars-Sinai Medical Center, Los Angeles, CA; Lynn S. Ashby, Barrow Neurological Institute, Phoenix, AZ; John DeGroot, MD Anderson Cancer Center, Houston, TX; Lawrence Cher, Austin Health Cancer Services; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Australia; Franz Payer, Medical University, Graz, Austria; Juliane M. Jürgensmeier, John Xu, and Qi Liu, AstraZeneca, Wilmington, DE; and Martin van den Bent, Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.2464DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021043PMC
September 2013

Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports.

Cancer Invest 2012 Dec 8;30(10):712-20. Epub 2012 Oct 8.

Departments of Medical Oncology and Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/07357907.2012.727934DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536036PMC
December 2012

Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies.

Eur J Cancer 2012 Nov 22;48(16):3045-51. Epub 2012 Jun 22.

Department of Medical Oncology, Universitair Ziekenhuis Brussel, 1090 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2012.05.016DOI Listing
November 2012

Vemurafenib-induced neutrophilic panniculitis.

Melanoma Res 2012 Oct;22(5):399-401

Department of Dermatology, St-Louis Hospital, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0b013e3283570792DOI Listing
October 2012

Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.

Int J Oncol 2012 Sep 29;41(3):1029-35. Epub 2012 Jun 29.

Laboratory of Molecular Oncology and Department of Medical Oncology, University Hospital Brussels, Free University Brussels, 1090 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2012.1539DOI Listing
September 2012

Temozolomide dosing regimens for glioma patients.

Curr Neurol Neurosci Rep 2012 Jun;12(3):286-93

Department of Neurology, Medical School, University of Marburg, Baldinger Strasse, 35043 Marburg, Germany.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11910-012-0262-y
Publisher Site
http://dx.doi.org/10.1007/s11910-012-0262-yDOI Listing
June 2012

Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.

Mol Ther 2012 May 28;20(5):1063-74. Epub 2012 Feb 28.

Laboratory of Molecular and Cellular Therapy, Department of Immunology-Physiology, Medical School of the Vrije Universiteit Brussel (VUB), Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/mt.2012.11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3345975PMC
May 2012

Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens.

J Immunol Methods 2012 Mar 16;377(1-2):23-36. Epub 2012 Jan 16.

Laboratory of Molecular and Cellular Therapy, Department of Physiology-Immunology, Medical School of the Vrije Universiteit Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jim.2011.12.010DOI Listing
March 2012

Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.

Anticancer Res 2011 Dec;31(12):4457-63

Laboratory of Molecular Oncology and Department of Medical Oncology, Oncology center, UZ Brussels, University Hospital Brussels, Free University Brussels, Brussels, Belgium.

View Article

Download full-text PDF

Source
December 2011

Long-term disease-free survival following dendritic cell therapy and resection of small bowel melanoma metastases - a case report.

Anticancer Res 2011 Oct;31(10):3579-83

Department of Surgery, UZ Brussel, Laarbeeklaan 101, B-1090 Brussels, Belgium.

View Article

Download full-text PDF

Source
October 2011

18F-FDG PET/CT imaging of an anti-CTLA-4 antibody-associated autoimmune pancolitis.

Eur J Nucl Med Mol Imaging 2011 Jul 2;38(7):1390-1. Epub 2011 Mar 2.

Department of Radiology, Universitair Ziekenhuis Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-011-1749-5DOI Listing
July 2011

Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.

Future Oncol 2011 Mar;7(3):339-54

Department of Surgery, Division of Neurosurgery, 047 Baker House, Duke University Medical Center, Box 3624, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.11.8DOI Listing
March 2011

Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation.

Methods Mol Biol 2010 ;629:405-52

Laboratory of Molecular and Cellular Therapy, Department of Physiology - Immunology, Medical School of the Vrije Universiteit Brussel (VUB), Brussels, Belgium.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-1-60761-657-3_27
Publisher Site
http://dx.doi.org/10.1007/978-1-60761-657-3_27DOI Listing
June 2010

Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.

Cancer 2010 Jun;116(12):2868-77

Department of Medical Oncology, Oncology Center, UZ Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25035DOI Listing
June 2010

The role of cytotoxic drugs in the treatment of central nervous system gliomas.

Acta Neurol Belg 2010 Mar;110(1):1-14

Medical Oncology, UZ Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
March 2010

Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.

Surg Neurol 2009 Oct 15;72(4):423-8. Epub 2009 Jan 15.

Department of Neurosurgery, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S009030190800873
Publisher Site
http://dx.doi.org/10.1016/j.surneu.2008.09.023DOI Listing
October 2009

Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.

Clin Cancer Res 2009 May 5;15(10):3366-75. Epub 2009 May 5.

Laboratory of Molecular and Cellular Therapy, Department of Physiology-Immunology, Medical School of the Vrije Universiteit Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-2982DOI Listing
May 2009

Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA.

Mol Ther 2008 Jun 22;16(6):1170-80. Epub 2008 Apr 22.

Laboratory of Molecular and Cellular Therapy, Department of Physiology-Immunology, Medical School of the Vrije Universiteit Brussel, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S152500161631744
Publisher Site
http://dx.doi.org/10.1038/mt.2008.77DOI Listing
June 2008

Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers.

BMC Cancer 2008 Jan 8;8. Epub 2008 Jan 8.

Laboratory for Molecular Oncology, Universitair Ziekenhuis, Vrije Universiteit Brussel, 1090 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-8-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2266762PMC
January 2008

Current approaches in dendritic cell generation and future implications for cancer immunotherapy.

Cancer Immunol Immunother 2007 Oct 15;56(10):1513-37. Epub 2007 May 15.

Laboratory of Molecular and Cellular Therapy, Department of Physiology and Immunology, Medical School of the Vrije Universiteit Brussel, Laarbeeklaan 103/E, 1090, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-007-0334-zDOI Listing
October 2007

123I-2-iodo-tyrosine, a new tumour imaging agent: human biodistribution, dosimetry and initial clinical evaluation in glioma patients.

Eur J Nucl Med Mol Imaging 2007 Jul 20;34(7):994-1002. Epub 2007 Jan 20.

Department of Nuclear Medicine, Academic Hospital, Vrije Universiteit Brussel AZ-VUB, Laarbeeklaan 101, 1090 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-006-0303-3
Publisher Site
http://dx.doi.org/10.1007/s00259-006-0303-3DOI Listing
July 2007

A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44.

Cancer Immunol Immunother 2007 Jun 10;56(6):753-9. Epub 2006 Nov 10.

Ludwig Institute for Cancer Research, 74 avenue Hippocrate, UCL 7459, 1200 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-006-0244-5DOI Listing
June 2007

PET and CT demonstration of metastatic invasion of the thoracic duct.

Eur J Nucl Med Mol Imaging 2006 Mar 21;33(3):392. Epub 2005 Dec 21.

Department of Radiology, Free University of Brussels, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-005-1980-zDOI Listing
March 2006

Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1.

Cancer Immunol Immunother 2006 Feb 27;55(2):178-84. Epub 2005 Sep 27.

Christian de Duve Institute of Cellular Pathology, University of Louvain, Avenue Hippocrate 74, UCL 7459, 1200 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-005-0063-0
Publisher Site
http://dx.doi.org/10.1007/s00262-005-0063-0DOI Listing
February 2006

The role of chemotherapy in the treatment of low-grade glioma. A review of the literature.

Acta Neurol Belg 2005 Sep;105(3):137-43

Medische Oncologie, Oncologisch Centrum, Academisch Ziekenhuis Vrije Universiteit Brussel (AZ-VUB), Brussel, Belgium.

View Article

Download full-text PDF

Source
September 2005

Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells.

J Gene Med 2004 Nov;6(11):1175-88

Laboratory of Molecular and Cellular Therapy, Department of Physiology and Immunology, Medical School of the Vrije Universiteit Brussel, 1090 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jgm.615DOI Listing
November 2004

Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.

J Neurooncol 2004 Oct;70(1):37-48

Medical Oncology, UZ-Gasthuisberg KUL, Katholieke Universiteit Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
October 2004

Efficacy of infusional biomodulated 5-fluorouracil in metastatic colorectal cancer after raltitrexed failure.

Anticancer Res 2004 May-Jun;24(3b):2037-40

Medical Oncology, Oncologisch Centrum, AZ-VUB, Brussels, Belgium.

View Article

Download full-text PDF

Source
September 2004

Restoration of an impaired TGF-beta1 autocrine growth-inhibitory circuit results in growth inhibition of ovarian epithelial cancer cells and complete inhibition of their tumorigenicity.

Cancer Detect Prev 2003 ;27(5):380-8

Laboratory of Medical and Molecular Oncology, Oncologisch Centrum, AZ-VUB, Laarbeeklaan 101, B-1090, Jette, Belgium.

View Article

Download full-text PDF

Source
August 2004